Articles cités:
Dolat, Marine et al. “Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure.” Pharmaceuticals (Basel, Switzerland) vol. 13,11 416. 23 Nov. 2020, doi:10.3390/ph13110416
Macaire, Pauline et al. “Therapeutic drug monitoring as a tool to optimize 5-FU-based chemotherapy in gastrointestinal cancer patients older than 75 years.” European journal of cancer (Oxford, England : 1990) vol. 111 (2019): 116-125. doi:10.1016/j.ejca.2019.01.102
Morawska, Katarzyna et al. “5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer.” Oncotarget vol. 9,14 11559-11571. 30 Jan. 2018, doi:10.18632/oncotarget.24338
Des recommandations pour prévenir certaines toxicités sévères des chimiothérapies par fluoropyrimidines
